BIA
SRPT icon

Benchmark Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Benchmark Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,275
Closed -$277K – 91
2024
Q4 		$277K Hold
2,275
– – 0.18% 76
2024
Q3 		$284K Hold
2,275
– – 0.2% 73
2024
Q2 		$359K Sell
2,275
-105
-4% -$13.5K 0.26% 67
2024
Q1 		$308K Sell
2,380
-285
-11% -$34.9K 0.24% 76
2023
Q4 		$257K Sell
2,665
-640
-19% -$61.4K 0.24% 77
2023
Q3 		$401K Sell
3,305
-330
-9% -$37.3K 0.4% 61
2023
Q2 		$416K Sell
3,635
-5
-0.1% -$645 0.38% 63
2023
Q1 		$502K Sell
3,640
-123
-3% -$16K 0.52% 54
2022
Q4 		$488K Sell
3,763
-120
-3% -$13.9K 0.52% 56
2022
Q3 		$429K Buy
3,883
+110
+3% +$11.1K 0.46% 60
2022
Q2 		$283K Sell
3,773
-150
-4% -$11K 0.3% 84
2022
Q1 		$306K Sell
3,923
-70
-2% -$5.36K 0.23% 106
2021
Q4 		$360K Buy
+3,993
New +$341K 0.3% 80

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Benchmark Investment Advisors's SRPT Position: Q1 2025 in Review

Benchmark Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,275 shares — an estimated $277K sold.

Benchmark Investment Advisors first reported a position in SRPT in Q4 2021 and held it in 13 quarters. The position peaked at $502K in Q1 2023. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Benchmark Investment Advisors reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Benchmark Investment Advisors sold 2,275 Sarepta Therapeutics shares in Q1 2025, an estimated $277K.
  • Benchmark Investment Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 13 quarters.
  • Benchmark Investment Advisors's Sarepta Therapeutics position peaked at $502K in Q1 2023.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Benchmark Investment Advisors's 13F filing for Q1 2025, filed 15 May 2025.